paritaprevir

inhibits HCV NS3 protease

Also Known As:

(2R,6S,12Z,13aS,14aR,16aS)-N-(cyclopropylsulfonyl)-6-(5-methylpyrazin-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16atetradecahydrocyclopropa(E)pyrrolo(1,2-a)(1,4)diazacyclopentadecine-14a(5H)-carboxamide; ABT 450; ABT-450; ABT450; paritaprevir dihydrate; paritaprevir hydrate; veruprevir; veruprevir anhydrous

Networked: 288 relevant articles (43 outcomes, 83 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Khatri, Amit: 22 articles (02/2019 - 01/2014)
2.	Pilot-Matias, Tami: 21 articles (03/2019 - 01/2013)
3.	Menon, Rajeev M: 20 articles (02/2019 - 07/2015)
4.	Cohen, Daniel E: 19 articles (01/2020 - 01/2013)
5.	Dutta, Sandeep: 14 articles (10/2017 - 07/2015)
6.	Zha, Jiuhong: 13 articles (01/2020 - 07/2015)
7.	Poordad, Fred: 13 articles (05/2019 - 01/2013)
8.	Polepally, Akshanth R: 13 articles (01/2019 - 07/2015)
9.	Podsadecki, Thomas: 12 articles (07/2017 - 01/2013)
10.	Redman, Rebecca: 11 articles (03/2019 - 06/2015)

Related Diseases

1.	Infections 01/01/2016 - "Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies." 01/01/2018 - "Although there was a higher rate of virologic failure in patients with GT2b infection, the resistance analyses presented in this report support the conclusion that testing for baseline resistance-associated polymorphisms is not warranted for HCV GT2-infected patients treated with a regimen of ombitasvir/paritaprevir/ritonavir + ribavirin for 16 weeks." 11/01/2017 - "Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis." 05/01/2016 - "Paritaprevir is a direct acting antiviral agent for use as part of a multidrug hepatitis C virus infection treatment regimen. " 01/01/2016 - "Paritaprevir is a direct-acting antiviral agent that is a component of approved multidrug regimens used in the treatment of hepatitis C virus (HCV) infection. "
2.	Fibrosis (Cirrhosis) 03/01/2020 - "Since 2017 treatment-naïve patients infected with genotype 1b of hepatitis C virus and minimal or moderate fibrosis can be treated with Ombitasvir/Paritaprevir/ritonavir + Dasabuvir (OPrD) for 8 weeks according to updated Summary of Product Characteristics. " 01/01/2018 - "12 weeks ombitasvir/paritaprevir-ritonavir + ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis." 01/01/2019 - "This open-label, multicentre, Phase 3 study evaluated the safety and efficacy of ombitasvir/paritaprevir/ritonavir + dasabuvir (OBV/PTV/r + DSV) with low-dose ribavirin for 12 weeks in genotype 1a-infected patients without cirrhosis. " 01/01/2019 - "Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis." 10/01/2015 - "Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis."
3.	Chronic Hepatitis C 09/10/2023 - "Paritaprevir is an orally bioavailable, macrocyclic drug used for treating chronic Hepatitis C virus infection. " 01/01/2019 - "Ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin (OBV/PTV/r ± DSV ± RBV) regimens show high efficacy and good tolerability in clinical trials for chronic hepatitis C virus (HCV) genotypes (GT) 1 or 4. To evaluate whether these results translate to clinical practice, data were pooled from observational studies across 13 countries. " 12/01/2017 - "The direct-acting protease inhibitor paritaprevir is a new pharmaco-logic option available for treatment of chronic hepatitis C (HCV). " 06/01/2023 - "Paritaprevir is a potent inhibitor of the NS3/4A protease used to treat chronic hepatitis C virus infection. " 11/01/2018 - "The study included patients from 16 hepatologic centres involved in the AMBER, investigator-initiated study on treatment of chronic hepatitis C patients within a programme preceding EU registration of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin. "
4.	Hepatitis C 12/01/2017 - "Effect of Hepatitis C Treatment with Ombitasvir/Paritaprevir/R + Dasabuvir on Renal, Cardiovascular and Metabolic Extrahepatic Manifestations: A Post-Hoc Analysis of Phase 3 Clinical Trials." 01/01/2018 - "Effect of ombitasvir/paritaprevir/ritonavir + dasabuvir regimen on health-related quality of life for patients with hepatitis C." 01/01/2016 - "Metabolism and Disposition of the Hepatitis C Protease Inhibitor Paritaprevir in Humans." 04/01/2014 - "New antiviral agents for the treatment of hepatitis C: ABT-450." 01/01/2018 - "Gadoxetic acid-enhanced magnetic resonance imaging to predict paritaprevir-induced hyperbilirubinemia during treatment of hepatitis C."
5.	Chronic Renal Insufficiency 02/01/2023 - "Efficacy and safety of ombitasvir/paritaprevir/ritonavir-based therapy in HCV patients with chronic kidney disease." 01/01/2017 - "The aim of this study was to evaluate the effectiveness and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) ± dasabuvir (DSV) ± ribavirin (RBV) in patients with stage 4 or 5 chronic kidney disease (CKD) and HCV genotype 1 or 4 infection in real clinical practice, and to investigate pharmacological interactions. " 01/01/2018 - "Limited data have shown high efficacy of co-formulated ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) in the treatment of hepatitis C virus (HCV) genotype (GT)-4, and combined with dasabuvir (DSV) in GT1 patients, with chronic kidney disease (CKD) stages 4-5 (<30 mL/min/1.73 m2 ). " 04/01/2019 - "The 3D regimen, a combination of four drugs (ombitasvir, paritaprevir, dasabuvir, and ritonavir), has recently been used for patients with chronic kidney disease infected with genotype 1a and 1b HCV. " 06/01/2018 - "The aim of this study was to clarify the effects and safety of ombitasvir/paritaprevir/ritonavir (OBT/PTV/r) therapy in genotype 1b chronic hepatitis C patients with non-dialysis chronic kidney disease (CKD). "

Related Drugs and Biologics

1.	ombitasvir
2.	Ritonavir (Norvir)
3.	Ribavirin (Virazole)
4.	dasabuvir
5.	paritaprevir
6.	Interferons
7.	Sofosbuvir
8.	daclatasvir
9.	Antiviral Agents (Antivirals)
10.	Simeprevir

Related Therapies and Procedures

1.	Therapeutics
2.	Liver Transplantation
3.	Aftercare (After-Treatment)
4.	Duration of Therapy
5.	Renal Dialysis (Hemodialysis)